Genistein-Inhibited Cancer Stem Cell-Like Properties and Reduced Chemoresistance of Gastric Cancer by Huang, Weifeng et al.
Int. J. Mol. Sci. 2014, 15, 3432-3443; doi:10.3390/ijms15033432 
 
International Journal of  
Molecular Sciences 
ISSN 1422-0067  
www.mdpi.com/journal/ijms 
Article 
Genistein-Inhibited Cancer Stem Cell-Like Properties and 
Reduced Chemoresistance of Gastric Cancer  
Weifeng Huang 1,2, Chunpeng Wan 3, Qicong Luo 1, Zhengjie Huang 1 and Qi Luo 1,* 
1 Department of Surgical Oncology, First Affiliated Hospital of Xiamen University &  
Xiamen Cancer Center, Xiamen 361003, Fujian, China; E-Mails: huangwf006@163.com (W.H.); 
qcluo@xmu.edu.cn (Q.L.); h74zj@126.com (Z.H.) 
2 Medical College, China Three Gorges University, Yichang 443002, Hubei, China 
3 Jiangxi Key Laboratory for Postharvest Technology and Nondestructive Testing of Fruits & Vegetables, 
College of Agronomy, Jiangxi Agricultural University, Nanchang 330045, Jiangxi, China;  
E-Mail: lemonwan@126.com 
* Author to whom correspondence should be addressed; E-Mail: luoqixmzsh@126.com;  
Tel.: +86-592-8891861; Fax: +86-592-2139526. 
Received: 4 December 2013; in revised form: 12 February 2014 / Accepted: 13 February 2014 / 
Published: 25 February 2014 
 
Abstract: Genistein, the predominant isoflavone found in soy products, has exerted its 
anticarcinogenic effect in many different tumor types in vitro and in vivo. Accumulating 
evidence in recent years has strongly indicated the existence of cancer stem cells in gastric 
cancer. Here, we showed that low doses of genistein (15 µM), extracted from  
Millettia nitida Benth var hirsutissima Z Wei, inhibit tumor cell self-renewal in two types 
of gastric cancer cells by colony formation assay and tumor sphere formation assay. 
Treatment of gastric cancer cells with genistein reduced its chemoresistance to 5-Fu 
(fluorouracil) and ciplatin. Further results indicated that the reduced chemoresistance may 
be associated with the inhibition of ABCG2 expression and ERK 1/2 activity. Furthermore, 
genistein reduced tumor mass in the xenograft model. Together, genistein inhibited gastric 
cancer stem cell-like properties and reduced its chemoresistance. Our results provide a 
further rationale and experimental basis for using the genistein to improve treatment of 
patients with gastric cancer.  
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Soy isoflavones have been identified as dietary components contributing to relatively lower rates of 
different types of cancer in Asian counties including China. Millettia nitida Benth var hirsutissima  
Z Wei (Fengcheng Jixueteng in Chinese) is a perennial herb distributed in Jiangxi and Fujian provinces 
of Southeast China [1]. In Chinese folk medicine, it is used to treat dysmenorrhea, irregular 
menstruation, rheumatic pain, aching pain, as well as paralysis [2]. Genistein (4',5,7-trihydroxyisoflavone), 
the predominant isoflavone was found in soy products. Laboratory research from the last few decades 
have provided convincing evidence of the inhibitory effects of genistein on various cancer cells 
including breast, prostate, gastric, ovarian cancer cell [3]. It has been demonstrated that genistein 
functions as a promising chemopreventive agent to inhibit carcinogenesis through the modulation of 
genes that intimately related to the regulation of programmed cell death and cell cycle [4,5]. 
Additionally, genistein has been shown to inhibit to the angiogenesis and metastasis [6,7], imply the 
pleiotropic effects of genistein on the inhibition of carcinogenis and cancer cell growth. There may be 
other mechanisms of inhibition of cancer by genistein that are as yet undiscovered. 
Unlike most cancer cells with a tumor, the cancer stem cells (CSCs) hypothesis suggests that they 
are a unique subpopulation in the tumors, which posses the ability to initiate tumor growth,  
self-renewal, and resist chemotherapeutic drugs, thereby causing relapse of the disease [8]. Thus, drugs 
that inhibited cancer cell self-renewal and reduced chemoresistance offer great promise for cancer 
treatment. Worldwide, gastric cancer is the fourth most common cancer and the second highest cause 
of cancer-related morbidity (1 million deaths per year) after lung cancer [9]. Increasing evidences have 
indicated the existence of gastric cancer stem cells (GCSCs). Shigeo TakaiShi et al. showed for the 
first time that CD44 appears to be the most useful marker for prospective purification of GCSCs [10]. 
In the subsequent study using CD44 and CD54, GCSCs were successfully isolated from the blood of 
gastric cancer patients [11]. In a recent study, the CD90 Marker was used [12]. The CD44 and CD24 
combination has also been used for the isolation attempt [13]. In addition, stem cell markers such as 
OCT4, Sox2, Nanog have been recommended for identifying GCSCs [14]. Moreover, cells isolated 
from the gastric cancer cell lines using the tumor sphere culture technique exhibited characteristics of 
CSCs with high expression levels of stem cell marks with a mutipotent capacity of differentiation and 
enhanced tumorigenicity [15].  
As mentioned above, a number of reports have demonstrated the inhibiting carcinogenesis by 
genistein through the modulation of multiple regulatory pathways in the mammary tumor model, 
including programmed cell death, cell cycle, angiogenesis and metastasis. However, the potential 
inhibitory of genistein on the gastric cancer cell stem-like properties is still unclear. In the present 
study, our results demonstrated that gastric cancer cells treated with genistein inhibited the gastric 
cancer cell stem-like properties, such as self-renewal ability, drug resistance and tumorigenicity, which 
are associated with the decreased expression of stemness-related genes and the drug resistance  
gene ABCG2.  




2.1. Identification of Genistein 
The isolated compound was identified by a combination of NMR and mass spectral data and by 
comparison of these to published in the literature.  
Compound 1, colorless needle crystal (Figure 1); UV-vis (MeOH) max = 269 nm; (−) ESI-MS,  
m/z 269.03 [M − H]−, calcd for molecular formula C15H10O5. 1H-NMR (600 MHz, CD3COCD3)  
δ: 13.02 (1H, s), 9.62 (1H, s), 8.52(1H, s), 8.16 (1H, s, H-2), 7.44 (2H, d, J = 8.5 Hz, H-2', 6'), 6.88 
(2H, d, J = 8.5 Hz, H-3', 5'), 6.40 (1H, d, J = 2.0 Hz, H-6), 6.25 (1H, d, J = 2.0 Hz, H-8).  
13C-NMR (150 MHz, CD3COCD3) δ: 154.2 (C-2), 124.0 (C-3), 170.1 (C-4), 163.7 (C-5), 99.8 (C-6), 
164.8 (C-7), 94.2 (C-8), 159.1 (C-9), 106.0 (C-10), 123.0 (C-1'), 131.2(C-2',6'), 115.8 (C-3',5'),  
158.4 (C-4'). The NMR data were consistent with the literature and compound 1 was identified as 
genistein [16]. 







2.2. Genistein Inhibited GCSCs Self-Renewal Properties and Negatively Correlated with  
GCSCs Characteristics 
Tumor sphere assay and soft agar colony formation assay have been used to identity stem cell 
widely in vitro assays [17]. We first assayed the colony formation capacity in MGC-803 and  
SGC-7901 under the treatment of genistein. The results showed genistein inhibited the colony 
formation capacity in these cells in dose-dependent manner as shown in Figure 2A,B. Even 10 μM 
concentrations of genistein could cause significant inhibition of colony formation in MGC-803 
(28.62%, p < 0.001, Figure 2A) and SGC-7901 (60.68%, p < 0.01, Figure 2B).  
We then examined the tumor sphere formation capacity in MGC-803 and SGC-7901 under the 
treatment of genistein. Our results showed that the gastric cancer cells sphere formation capacity was 
inhibited by genistein in a dose-dependent manner, as shown in Figure 2. At 10 μM genistein, the 
inhibition efficiency of tumor sphere formation is 53.80% (MGC-803, p < 0.001, Figure 2C) and 
58.58% (SGC-7901, p < 0.001, Figure 2D), respectively. 
Moreover, we compared GCSCs marker expression in monolayer MGC-803 cells, MGC-803 
spheres and MGC-803 spheres treated with 15 μM genistein by Real-Time PCR. The results showed 
that the spheres expressed much higher levels of GCSCs markers, such as OCT-4, Sox2, Nanog, CD44, 
and CD90 than the monolayer cells. The induction of GCSCs markers were greatly suppressed in the 
spheres treated with 15 μM genistein compared with the spheres that were untreated (Figure 2E). 
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Figure 2. Genistein-inhibited gastric cancer stem cells (GCSCs) self-renewal properties 
and negatively correlated with GCSCs characteristics. (A) Genistein inhibited the colony 
formation capacity in MGC-803 in a dose-dependent manner. Representative photograph 
of colony was shown on the top. Statistical analysis was shown on the bottom;  
(B) Genistein inhibited the colony formation capacity in SGC-7901 in a dose-dependent 
manner. Representative photograph of colony was shown on the top. Statistical analysis 
was shown on the bottom; (C) Genistein inhibited the tumor sphere formation capacity in 
MGC-803 in a dose-dependent manner; (D) Genistein inhibited the tumor sphere formation 
capacity in SGC-7901 in a dose-dependent manner; (E) Several gastric stem cell markers 
expression in tumorspheres and monolayer cells. Data are the mean ± SEM of  
three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control.  
NS, no significance. 
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Figure 3. Genistein reduced gastric cancer cell chemoresistance. (A) Genistein reduced 
MGC-803 chemoresistance. MGC-803 pre-treated with genistein (15 μM) or not for 24 h, 
and then various concentration of cisplatin were used to treat MGC-803 cells. Cell viability 
was determined by MTT assay; (B) Genistein reduced MGC-803 chemoresistance.  
MGC-803 pre-treated with genistein (15 μM) or not for 24 h, and then various 
concentration of 5-Fu were used to treat MGC-803 cells. Cell viability was determined by 
MTT assay; (C) Drug resistant genes expression in MGC-803 under the treatment of 
genistein (15 μM); (D) Genistein inhibited ERK 1/2 activity. pERK 1/2 and ERK 1/2 
expression in MGC-803 treated with indicated concentration of genistein were detected by 
western blotting. Data are the mean ± SEM of three independent experiments. * p < 0.05, 
** p < 0.01, *** p < 0.001 vs. control.  
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2.3. Genistein Reduced Gastric Cancer Cell Chemoresistance 
Studies in the past have suggested that chemoresistance is another characteristic of CSCs [18]. We 
next investigated whether genistein would influence the chemoresistance of MGC-803 cells. For this 
purpose, MGC-803 pre-treated with genistein (15 μM) or not for 24 h and then various concentrations 
of two chemotherapy drugs, 5-Fu and cisplatin, were used to treat the cells. As showed in Figure 3A,B, 
genistein enhanced chemosensitivity to these chemotherapy drugs. Moreover, we detected 
chemoresistant genes expressed in MGC-803 under the treatment of genistein (15 μM). As shown in 
Figure 3C, ABCC1, ABCC5 and ABCG2 expression were repressed under the treatment of genistein 
(15 μM). Especially, the inhibition efficiency of ABCG2 was about 73.73% under the treatment of 
genistein in compared with the control. 
It has been reported that ERK 1/2 activity plays an important role in regulating the ABCG2 
expression. Genistein has been found to be effective in preventing cytokine-induced ERK 1/2 
activation. To evaluate the role of ERK 1/2 activity in genistein reduced gastric cancer cell 
chemoresistance we detected the ERK 1/2 and phospho-ERK 1/2 in MGC-803 under the treatment of 
genistein. As shown in Figure 3D, phospho-ERK 1/2 expression was inhibited by genistein in a  
dose-dependent manner; at the same time, the total ERK 1/2 expression was unchanged. 
2.4. Genistein Reduced the Tumorigenicity in Vivo 
It has been shown that the tumorigenicity in vivo correlates with the sphere formation ability of 
tumor cells in vitro. To test the effect of genistein on the tumorigenicity of gastric cancer cells,  
MGC-803 Cell (5 × 106) were inoculated in to nude BALB/C mice. When the tumors had developed 
for 7 days, the mice were randomly distributed into two groups, and were untreated or treated with 
genistein. We found the size and weight of xenograft tumors treated with genistein was significantly 
smaller than the control tumors (Figure 4). These results thus demonstrated that genistein efficiently 
attenuated the tumorigenicity of gastric cancer cells. 
Figure 4. Genistein reduced the tumorigenicity in vivo. (A) Tumors produced by  
MGC-803. MGC-803 Cell (5 × 106) were injected subcutaneously in the right flank of 
nude mice per mouse respectively (n = 4). And when the tumors developed in 7 days, the 
mice were was randomly distributed into two groups, and were untreated or treated by i.p. 
injections every day with genistein (1.5 mg/kg); (B) Tumor growth curves were monitored 
during the experimental period (n = 4) Data represent the mean ± SEM of three 
independent experiments. * p < 0.05, ** p < 0.01 vs. control. 
 
(A) 
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Figure 4. Cont. 
























Genistein, the predominant component isoflavone in soy products, has been found to inhibit various 
cancer cells. It has been demonstrated that genistein prevents carcinogenesis by modulating multiple 
signaling pathways, such as programmed cell death, cell cycle, angiogenesis and so on [3]. Cancer 
stem cells hypothesis suggested that CSCs is the main cause of relapse in cancer patients [17]. We 
speculated that inhibiting CSCs properties may be a potential mechanism of preventing carcinogenesis 
by genistein. The tumor sphere assay has been used to identity stem cells, as shown in Figure 2C,D. 
CSCs markers were greatly induced in our experimental system. Our results demonstrated that 
genistein inhibits gastric cancer cell self-renewal capacity (Figure 2A–D). Consistent with the 
inhibitory effects, genistein suppressed the GCSCs markers induction (Figure 2E). 
Chemoresistance is another characteristic of CSCs [17]. Our results showed that genistein enhanced 
gastric cancer cell chemosensitivity to 5-Fu and cisplatin. The chemosensitivity is associated with 
downregulation of ABCC1, ABCC5, ABCG2 and ERK 1/2 activity (Figure 3C,D). Genistein inhibited 
ABCG2 mRNA expression. At the same time, genistein inhibited the tumor sphere formation. Our 
results are consistent with other reports that ABCG2 not only plays a major role in multidrug 
resistance but can also be characterized as a CSCs marker [19]. 
ERK 1/2 have been demonstrated to play an important role in regulating the ABCG2 expression [20], 
and genistein could prevent ERK 1/2 activity [21]. We found that genistein inhibited phospho-ERK 1/2 in 
dose-dependent manner. Our data indicated that genistein enhanced gastric cancer cell chemosensitivity 
and is associated with the suppression of ERK 1/2 activity. 
4. Experimental Section 
4.1. Extraction and Isolation 
The stems of the Millettia nitida Benth var hirsutissima Z Wei were collected locally from 
Fengcheng (Fengcheng, Jiangxi, China) in May 2008. Voucher specimens (ID: 200805) are deposited 
in the Medical College, China Three Gorges University (Yichang, Hubei, China). The stems (2 kg) 
were powered and extracted exhaustively with ethanol (3 × 8 L) at room temperature to yield a dried 
ethanol extract (178 g). The extract was re-suspended in H2O (3 L) and partitioned with CHCl3  
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(3 × 3 L), EtOAc and n-buthanol respectively. The CHCl3 extract (26.8 g) was chromatographed on  
a silica gel column (4 × 40 cm) eluting with a gradient system of Petroleum Ether/Acetone (10:1 to 
1:2, v/v) to afford five sub-fractions (Fr.1–Fr.5) which were combined based on TLC analyses. Fraction 
Fr.4 was further separated by Sephadex LH-20 (Springup, Beijing, China) and semi-preparative  
HPLC (SHIMADZU, Kyoto, Japan) to yield compound 1 (30.2 mg). 
4.2. Cell Cultures 
Human gastric cancer cell lines, MGC-803 and SGC-7901, were purchased from Institute of Cell 
Biology (Shanghai, China, http://www.cellbank.org.cn). Cells were maintained in Royal Park 
Memorial Institute-1640 (RPMI-1640). All cell culture media were supplemented with 10% fetal 
bovine serum (FBS), and 1% of penicillin-streptomycin (all from Invitrogen, Carlsbad, CA, USA, 
http://www.invitrogen.com). 
4.3. Soft Agar Colony Formation Assay 
Triplicate samples of cells (1 × 103) were resuspended in 1 mL of RPMI-1640 medium containing 
0.3% low-melt agarose, 10% fetal bovine serum, 1% of penicillin-streptomycin. The cell mixture was 
plated on top of solidified layer with the same RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) 
contain 0.6% low-met agarose. Plates were incubated for 3 weeks at 37 °C  in 5% CO2 in humidified 
incubator. MGC-803 and SGC-7901 cells treated with indicated concentration of genistein were plated 
in 0.3% agrose, and colonies were counted 3 weeks later. Then Colony formation was stained with  
0.01% crystal violet and photographed and counted. 
4.4. Tumorsphere Culture 
Tumorspere cultures were cultured in ultralow attachment six-well plate (Corning, Lowell, MA, 
USA) in suspention (500 cells/mL) in serum-free DMEM/F12 media, supplemented with 20 ng/mL 
epidermal growth factor (FGF, Sigma-Aldrich, Shanghai, China), 4 μg/mL insulin (Sigma-Aldrich, 
Shanghai, China), B27 supplement (1×, Invitrogen, Carlsbad, CA, USA), 1% of penicillin-streptomycin 
in humidified incubator at 37 °C  in 5% CO2. Tumor sphere formation was tested by placing gastric 
cancer cells in presence or absence of genistein under the conditions mentioned above. After 7 day 
incubation, the solid spheres were photographed and counted. The sphere size varies greatly from less 
than 50 µM to around 250 µM. With tumorspheres, the cells appear fused together and it is difficult to 
distinguish them as individual cells. With aggregated cells that were not counted, you can still see 
individual cells attached to one another.  
4.5. RNA Extraction, RT-PCR and Quantitative Real-Time PCR 
Total RNA was extracted using TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA) and reverse 
transcribed with R-PCR Quick Master Mix (Toyoba, Dalian, China) to produce cDNA. The primer 
sequences listed in Table 1 were used for Quantitative Real-Time PCR. Real-Time PCR was 
performed using SYBR Green-based detection in LightCycler®480 (Roche, Indianapolis, IN, USA) 
according to the manufacture’s instructions. OCT-4, Sox2, Nanog, CD44, and CD90 expression in 
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monolayer MGC-803 cells, MGC-803 spheres and MGC-803 spheres treated with 15 μM genistein 
were detected by Real-Time PCR. ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC6 and 
ABCG2 expression in MGC-803 cells treated with 15 μM genistein were detected by Real-Time PCR. 
GAPDH (glyceraldehyde-3'phosphate dehydrogenase) levels were used as normalization controls. 
4.5.1. Chemoresistance Assay 
The MTT assay (Cell titer 96® Aqueous One Solution Cell Proliferation Assay, Promega, Beijing, 
China) was used to assess the rates of resistance to drugs. Briefly, gastric cancer cells (2 × 103/well) 
were seeded in 96-well plates. After 24 h in presence or absence of genistein, the indicated concentration 
of chemotherapeutic drugs, 5-Fu (Sigma-Aldrich, Shanghai, China) and cisplatin (Sigma-Aldrich, 
Shanghai, China) were treated. 72 h later, the MTT assay was performed using iMarkmicroplate 
Absorbance Reader (Bio-RAD, Richmond, CA, USA) according to the manufacturer’s instructions. 
Table 1. Primers used for quantitative real-time PCR. 
Gene Primer direction Sequences 
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4.6. Cell Extraction and Western Blotting 
Western Blots were performed according to the protocols described previously [22]. The 
Immobilon Western Chemiluminescent HRP Substrate Kit (Millipore, MA, USA) was used to detect 
the results. Primary Antibody are ERK1/2 (AM076, 1:500; Beyotime, Nanjing, China), and  
phospho-ERK1/2 (AM071, 1:500; Beyotime, Nanjing, China). 
4.7. Tumor Growth in Xenografts 
MGC-803 Cell (5 × 106) were injected subcutaneously in the right flank of 8 female 6-week-old 
nude mice (Laboratory Animal Center, Xiamen University, Xiamen, China) per mouse respectively. 
When the tumors had developed for 7 days, the mice were randomly distributed into two groups, and 
were untreated or treated by i.p. injections every day with genistein (1.5 mg/kg). Tumor volumes (Tv) 
were measured every 3 days and calculated with the formula: Tv = L (Length) × W2 (Width)/2. 
4.8. Statistical Analysis 
Results are expressed as the means ± SEM. Statistical significance was determined by Student’s  
t test or a one-way or two-way analysis of variance (ANOVA) followed by Turkey’s test,  
as appropriate using Graphpad Prism statistics software (Graphpad Software, CA, USA).  
A p-value < 0.05 was considered statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.001). 
5. Conclusions 
Our present results showed that genistein inhibited GCSCs properties in vitro, reduced the gastric 
cancer cell tumorigenicity in vivo, enhanced chemosensitivity of gastric cancer cells and provided an 
experimental basis for using the genistein to improve treatment of patients with gastric cancer. 
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